Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Viracta Subsidiary, Inc.

Kura Oncology, Inc.

Araxes Pharma LLC

Xiaohu Deng

Neelakandha S Mani

Jimmy T Liang

Chennagiri R Pandit

Wei Xiao

Richard Apodaca

Curt A Dvorak

Jill A Jablonowski

Wanping Mai

Pingda Ren

Nicholas I Carruthers

Wenying Chai

Dale A Rudolph

Christa C Chrovian

Brett D Allison

Victoria Wong

Annette K Kwok

Biljana Nadjsombati

Robert C Mcrae

Victoria D Wong

Liansheng Li

Cheryl A Grice

Michael Anthony Letavic

J Guy Breitenbucher

Yun Long

Brad M Savall

Heather Renee Coate

Devin M Swanson

Laurent Gomez

Yuan Liu

John M Keith

John J M Wiener

Christine Fang Gelin

Natalie Anne Hawryluk

Brice M Stenne

Akinola Soyode-Johnson

Jason Christopher Rech

Genesis M Bacani

Dipanjan Sengupta

Virginia M Tanis

Jessica L Wall

Manuel Jesus Alcazar Vaca

Mark Seierstad

Susanne Lochner

Jose Ignacio Andres Gil

Jeffrey E Merit

Alejandro Santillán, Jr

Alice Lee-Dutra

Meri De Angelis

Diego Broggini

Aaron M Kearney

Kathleen C Sappey

Zachary S Sales

Alison L Chambers

Hartmut B Zinser

Adrienne M Landry-Bayle

Kia Sepassi

Patricia Andres

Joan M Pierce

Roger Paul Bakale

Eugene Y Cheung

Alvah T Wickboldt

Craig Michael Bowe

Stewart Jones

David Slack

Alejandro Santillan

Anne M Fourie

John J Wiener

John JM Wiener

Anne M Fourine

Kathleen C Sappy

Described herein are crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile or solvate thereof.

Crystalline forms of a menin inhibitor

The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.

HDAC inhibitor solid state forms

The present disclosure relates to various solid-state forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. Such forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.

Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.

Synthesis of tipifarnib

The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention. 

P2X7 modulators and methods of use

Methods for preparing compounds having the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R, R, R, R, R, R, Rand R, are as defined herein are provided. Related compounds and methods for making the same are also provided.

Methods for preparation of quinazoline derivatives

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

This invention relates to methods of making pyrimidinyl-substituted imidazole compounds by sequential substitution of the 4- and 2-chloro groups of 2,4-dichloropyrimidine, nucleophilic substitution to form pyrimidinylalkyne derivatives, oxidation to the corresponding 1,2-diketones, and cyclocondensation reactions.

Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine

This invention concerns the synthesis of highly substituted pyrazoles, which are structural components of pharmacological compounds, through reaction of hydrazones with nitroolefins.

Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles

Certain methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds are disclosed. The compounds are of the class of quinoxaline sulfonamides and constitute CCK2 receptor modulators, useful in the treatment of gastrointestinal diseases.

Preparation of quinoxaline compounds

Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.

Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase

The present invention is directed to novel processes for the preparation of fused pyrazole compounds, useful for the treatment of disorders and conditions mediated by serotonin receptor activity.

Methods for the preparation of pyrazole-containing compounds

Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.

Fused heterocyclic compounds

Growing community of inventors

San Diego, CA, United States of America

Xiaohu Deng